Research
Hormonal
The monthly growth rates were 83.9% for Ozempic and 119.2% for Wegovy.
High monthly growth rates indicate a significant trend towards the use of GLP-1 receptor agonists for weight loss.
StrongSupportsmedium confidence
The monthly growth rates were 83.9% for Ozempic, 119.2% for Wegovy.
Why this rating
Based on the retrospective cohort study design involving a large database.
Source
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022
Jonathan H. Watanabe et al. · Journal of the American Pharmacists Association · 2023
DOI 10.1016/j.japh.2023.10.002
cohortCited 179×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →